POINT Biopharma Global Inc. (NASDAQ: PNT), a company engaged in the discovery, development, and global access to life changing radiopharmaceuticals, and Kinectrics Inc., a leading service provider to the nuclear power and electricity industry recently announced a long-term supply agreement for Ytterbium-176 (Yb-176) to support POINT’s in-house no-carrier added Lutetium-177 (n.c.a. Lu-177) production program.

To learn more about n.c.a. Lutetium-177 as well as other medical isotopes, attend POINT’s inaugural educational day on Dec 6, 2021 – register online at https://hub.pointbiopharma.com/dec2021.

To read more please visit:

POINT Biopharma and Kinectrics Announce Yb-176 Supply Agreement Enabling North American Production of n.c.a. Lu-177

Source: POINT Biopharma